Bluejay Therapeutics vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Bluejay Therapeutics is a clinical-stage biopharmaceutical company developing therapies for chronic hepatitis B and liver diseases; raised over $100M; lead candidate BJT-778 entered clinical trials;
About
Bluejay Therapeutics is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Redwood City, California. The company is focused on developing innovative therapies for chronic liver diseases, with hepatitis B virus (HBV) infection as its primary indication. Chronic HBV is a significant unmet medical need affecting an estimated 296 million people worldwide; while existing antivirals like tenofovir and entecavir suppress the virus effectively, they do not achieve a functional cure and require lifelong treatment. Bluejay''s therapeutic programs aim to achieve functional cure — defined as durable suppression of HBV surface antigen (HBsAg) after treatment ends — by targeting viral replication mechanisms and immune restoration simultaneously.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.